Navigation Links
Kogenate® FS, Antihemophilic Factor (Recombinant), for Hemophilia A Now Easier For People to Store at Home or On The Go
Date:4/25/2011

please visit http://kogenatefs.com/webapp/prescribing-information.jsp.

About Hemophilia A

Hemophilia A, also known as factor VIII deficiency or classic hemophilia, is largely an inherited bleeding disorder in which one of the proteins needed to form blood clots in the body is missing or reduced. Hemophilia A, the most common type of hemophilia, is caused by deficient or defective blood coagulation proteins, known as factor VIII. Hemophilia A is characterized by prolonged or spontaneous bleeding, especially into the muscles, joints, or internal organs.  Approximately one in 5,000 males born in the United States has hemophilia.

About Kogenate® FS

Indications and Usage

Kogenate® FS, antihemophilic factor (recombinant), is a recombinant factor VIII treatment indicated for the control and prevention of bleeding episodes and peri-operative management in adults and children (0-16 years) with hemophilia A. Kogenate® FS is also indicated for routine prophylaxis to reduce the frequency of bleeding episodes and the risk of joint damage in children with hemophilia A with no preexisting joint damage.

Important Safety Information

The most serious adverse reactions are systemic hypersensitivity reactions and the development of high-titer inhibitors necessitating alternative treatments to AHF.  The most common adverse reactions observed in clinical trials were inhibitor formation in previously untreated or minimally treated patients, skin-associated hypersensitivity reactions, infusion site reactions, and central venous access device (CVAD) line-associated infections.  

Kogenate® FS is contraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product or its components, including mouse or hamster proteins.

For imp
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Daiichi Sankyo Receives First Market Approval in Japan for LIXIANA® (edoxaban), a Direct Oral Factor Xa Inhibitor, for the Prevention of Venous Thromboembolism after Major Orthopedic Surgery
2. NephRx Corp. Awarded U.S. Patent for Use of Novel Growth Factor Peptide NX002 in Inflammatory Bowel Disease
3. Novo Nordisk Submits First Recombinant Treatment for Factor XIII Deficiency for U.S. Regulatory Approval
4. Success Factors and Failure Points in Biopharmaceutical Product Launches
5. CSL Behring Marks World Hemophilia Day with Coagulation Factor Donation to World Federation of Hemophilia
6. Inspiration Biopharmaceuticals Demonstrates Non-Inferiority of IB1001, Its Recombinant Factor IX for Hemophilia B
7. EDC Functionality, Ease of Data Entry, and Access to Data All Factors in University of Virginia Cancer Centers Selection of the OnCore Clinical Research Management System
8. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
9. Octapharma Clinical Trial Begins in the U.S. and Germany Treating Hemophilia A Patients with First Recombinant Factor VIII Derived from a Human Cell-Line
10. Cardium Announces New Research Findings: Excellagen Product Candidate Activates Platelet Release of PDGF, an Important Growth Factor Fundamental to the Wound Healing Process
11. Neurocrine Announces Top-Line Results of Corticotropin Releasing Factor Antagonist GSK561679 for Treatment of Major Depressive Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... FRANKLIN, Mass. , Aug. 27, 2015 /PRNewswire/ ... in the KSSTA Knee Journal, compared the Arthrosurface ... "inlay" Arthroplasty design, versus an "onlay" design implant ... showed similar improvements in function and pain scores, ... showed progression of osteoarthritis (OA). However, 53% of ...
(Date:8/27/2015)... According to a new market research report ... Standing, Bariatric ), Material (Nylon, Padded, Canvas), Usage Type (Disposable, Reusable), ... MarketsandMarkets, the Medical Lifting Sling Market is poised to reach USD ... a CAGR of 11.4 % from 2015 to 2020. ... data T ables and 65 F ...
(Date:8/27/2015)... , Aug. 27, 2015   Proxsys ... Provider (IOPP™) is expanding its population health ... medication-focused transition of care program for hospitals ... Management," provides hospitals with technology systems and ... measures that have been mandated by Center ...
Breaking Medicine Technology:Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3Medical Lifting Sling Market Worth USD 706.0 Million by 2020 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 3Medical Lifting Sling Market Worth USD 706.0 Million by 2020 4Rx Care Management by Proxsys Rx - Transition of Care Technology Helps Prevent Hospital Medication Errors 2
... Ontario, Dec. 12, 2011 Valeant Pharmaceuticals International, Inc. (NYSE: ... the Federal Trade Commission (FTC) voted unanimously to approve the ... dermatology unit of Sanofi (EURONEXT: SAN and NYSE: ... division of Janssen Pharmaceuticals, Inc. As a ...
... PharMEDium announced the first generation solution ... Operating Room (O.R.).  PharMEDium has developed the ... "Our certiMED™ system is designed to be ... Ready-to-Use O.R. syringe medications by providing a visual and ...
Cached Medicine Technology:Valeant Pharmaceuticals Receives Approval From FTC in Connection With Acquisition of Ortho Dermatologics and Dermik 2PharMEDium Adds O.R. Medication Verification System 2
(Date:8/28/2015)... ... ... The 6th Annual Survivor in the City, Chicago silent auction and ... to its cadre of widespread support—an official letter of support and gratitude from the ... community and the University of Illinois at Chicago’s Department of Neurosurgery, the Brain Aneurysm ...
(Date:8/28/2015)... ... August 28, 2015 , ... Saint ... grade protein with zero fat, carbs, sugar, gluten, lactose or caffeine in a ... for the 2015 SupplySide CPG Editor’s Choice Awards. , Five consumer packaged goods ...
(Date:8/28/2015)... Beach, FL. (PRWEB) , ... August 28, 2015 ... ... problems for businesses nationwide. Addictions specialist, Dr. James Strawbridge, gives a new approach ... believes that it should begin with the employer and employees getting together for ...
(Date:8/28/2015)... West Jordan, Utah (PRWEB) , ... August 28, ... ... has been awarded a three-year accreditation for its adolescent residential, counseling, day treatment ... Academy demonstrates that it meets international standards for quality and its pursuit of ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Quatela Center for ... is the first and only nonsurgical product approved by the Food and Drug Administration ... Quatela and Dr. William Koenig are among the premier cosmetic surgeons ...
Breaking Medicine News(10 mins):Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 3Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3Health News:West Ridge Academy Awarded CARF Three-Year Accrediation 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 3
... use of incense increases the risk of developing cancers of ... analysis, which the authors say is the first prospective investigation ... 2008 issue of CANCER, a peer-reviewed journal of ... of daily life in large parts of Asia. Researchers have ...
... Mich., Aug. 22 Stryker Corporation,(NYSE: SYK ) ... conferences:, September 3, 2008 - 9:45 a.m. ... Boston, Massachusetts, September 17, 2008 - 9:30 ... 2008 London, England, Simultaneous webcasts of the ...
... reduce unhealthy behaviors like binge drinking and eating junk ... But a new study in the Journal of Consumer ... to improve consumer health. , Authors Jonah Berger ... that linking a risky behavior with an "outgroup" (a ...
... hotel towels if they know other guests are doing ... Journal of Consumer Research examined participation rates in ... Authors Noah J. Goldstein (University of Chicago), Robert B. ... that the types of signs posted in hotel bathrooms ...
... Technology approved for control of food-borne pathogens in ... Robert Brackett, chief,science officer for the Grocery ... response to the U.S. Food & Drug,Administration (FDA) ... for,controlling food-borne pathogens in fresh iceberg lettuce and ...
... use eRx Network Medicare Part B transaction ... processing services in its stores nationwide, FORT WORTH, Texas, ... transaction services to the retail pharmacy,industry, announced today that it ... Part B claims, state,Medicaid DME claims and clinical administration programs ...
Cached Medicine News:Health News:Burning incense increases risk of respiratory tract cancers 2Health News:Stryker to Present at Investor Conferences 2Health News:Part of the in-group? A surprising new strategy helps reduce unhealthy behaviors 2Health News:A room with a viewpoint: conservation messages and motivation 2Health News:Grocery Manufacturers Association Strongly Supports U.S. Food & Drug Administration Decision on the Irradiation of Fresh Produce for Foodborne Pathogen Control 2Health News:eRx Network to Provide Transaction Processing and Revenue Cycle Management Services to Rite Aid 2
Clinical micro clamps by Acland. Matte finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface....
Clinical micro clamps by Acland. Matte finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface....
Extremely fine straight....
Curved delicate 5 mm blades....
Medicine Products: